Seattle Genetics says 79% of 33 patients had complete remission in trial Seattle Genetics announced that in an ongoing investigator-sponsored phase 2 clinical trial, patients with relapsed or refractory HL have been enrolled to determine whether ADCETRIS can replace the combination chemotherapy regimen ifosfamide, carboplatin and etoposide or be ... (more)
http://www.theflyonthewall.com/permalinks/entry.php/SGEN;ARMH;SVNT;GGB;DEOid1850291/SGEN;ARMH;SVNT;GGB;DEO-High-option-volume-stocks-SGEN-ARMH-SVNT-GGB-DEO
http://www.theflyonthewall.com/permalinks/entry.php/SGEN;ARMH;SVNT;GGB;DEOid1850291/SGEN;ARMH;SVNT;GGB;DEO-High-option-volume-stocks-SGEN-ARMH-SVNT-GGB-DEO
No comments:
Post a Comment